Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Novartis India Ltd

₹ 8061.81%
16 Jan 3:42 p.m. – close price
🔗novartis.in•BSE: 500672•NSE: NOVARTIND
Market Cap₹ 1,990 Cr.
Current Price₹ 806
High / Low₹ 1,100
Stock P/E18.6
Book Value₹ 314
Dividend Yield3.13 %
ROCE17.0 %
ROE13.2 %
Face Value₹ 5.00
Sales₹ 355 Cr.
OPM28.4 %
Mar Cap₹ 1,990 Cr.

ABOUT

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods.[1]It imports various medicines to India from different sources across the globe.[2]

KEY POINTS

BusinessThe company is primarily engaged in the pharmaceutical business in the area of pain management, organ transplantation, neuroscience, etc.[1]

Also present in buckets:
Preferential IssuanceJv Partnerships AcquisitionsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1669.2034.64400497.060.953124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1112.970.07
2.Divi's Lab.6233.9566.60165491.740.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7113.530.01
3.Torrent Pharma.4018.7562.76136012.730.81591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1213.260.33
4.Cipla1399.4020.77113039.590.941353.373.737589.447.6422.7228349.5725.405441.141351.173.3914.720.01
5.Lupin2174.2023.0799317.100.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0812.410.32
6.Dr Reddy's Labs1179.3017.0898427.950.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7412.950.16
7.Mankind Pharma2173.5551.3589725.230.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.968.890.55
8.Novartis India806.0018.651990.073.1324.2218.6790.333.7117.00354.7628.36106.5924.222.5710.770.01
–Median: 149 Co.390.630.091763.550.1113.4911.71161.7610.5814.89591.7315.9345.2613.963.078.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
102807691798581928793848890
Expenses
85736773626570686967606066
Operating Profit
168917172011241826242724
Other Income
78161217221010101111119
Profit before tax
21142328324121342835343733
Tax %
14%47%-7%27%27%36%31%24%26%28%14%26%26%
Net Profit
1882520242715262025292824
EPS in Rs
7.433.0810.138.219.5910.765.9510.428.2710.3111.8711.199.81

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
859870690656564491438381400379335356355
Expenses
861874656631570478426355373314270265254
Operating Profit
-1-43425-612122727656591101
Other Income
9510120771172783633-1758624241
Interest
0001626852111
Depreciation
4434331312106322
Profit before tax
909323792158862940-4115123130139
Net Profit
99791985778521021-410385101107
EPS in Rs
30.8324.7562.0420.3331.7420.974.088.46-1.5141.8634.5040.8743.18
Dividend Payout %
32%40%16%49%32%48%245%118%-663%113%72%61%–

Compounded Sales Growth

10 Years:-9%
5 Years:-4%
3 Years:-4%
TTM:3%

Compounded Profit Growth

10 Years:3%
5 Years:58%
3 Years:35%
TTM:22%

Stock Price CAGR

10 Years:0%
5 Years:3%
3 Years:7%
1 Year:-8%

Return on Equity

10 Years:9%
5 Years:9%
3 Years:13%
Last Year:13%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
16161614121212121212121212
Reserves
9459861,178906721747708699679763732773763
Borrowings
00000068622422754
Other Liabilities
241244239230377223289229242186173158153
Total Liabilities
1,2021,2461,4331,1501,1119821,0781,002958983925948932
Fixed Assets
886651576642419754
Gross Block
23.9826.089.8710.8212.0923.9385.0874.8132.9431.1525.979.08–
Accumulated Depreciation
16.1117.583.395.117.498.958.8010.909.2911.9019.034.54–
CWIP
0000000000000
Investments
0000000000000
Other Assets
1,1941,2381,4261,1441,1069671,001938934964918943928
Total Assets
1,2021,2461,4331,1501,1119821,0781,002958983925948932

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
-5-6057-41161-194-23-69394511375
Cash from Investing Activity
22719-63042469274569587-15333-3
Cash from Financing Activity
-38-38-39-332-268-30-41-37-36-30-121-64
Net Cash Flow
-20622-61251-3850-9-1190-139267

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
333527232834313741354541
Inventory Days
961039210484111117119117998274
Days Payable
10098898715816814513714810811293
Cash Conversion Cycle
29403040-45-2331910261522
Working Capital Days
3536-35-14-997-162-23-37-59-45
ROCE %
10%9%22%9%17%12%5%6%6%15%16%17%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
70.68%70.68%70.68%70.68%70.68%70.68%70.68%70.68%70.68%70.68%70.68%70.68%70.68%
FIIs
0.17%0.17%0.23%0.32%0.19%0.19%0.19%0.19%0.19%0.19%0.19%0.19%0.19%
DIIs
0.77%0.77%0.75%0.52%0.52%0.52%0.52%0.52%0.53%0.53%0.53%0.53%0.63%
Public
28.37%28.38%28.34%28.47%28.60%28.61%28.60%28.61%28.60%28.61%28.60%28.61%28.50%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Novartis India Completes Postal Ballot Notice E-Mailing, Publishes Newspaper Advertisements

17th April 2026, 4:40 pm

Novartis India Files SEBI Dematerialisation Certificate for FY26

13th April 2026, 9:47 pm

Novartis India Limited Notifies on Postal Ballot/E-voting Through Newspaper Advertisements

13th April 2026, 9:31 pm

Novartis AG to Sell 70.68% Stake in Novartis India to Three Acquirers

8th April 2026, 4:08 am

Novartis India to approve FY26 audited financials on May 12; trading window closes April 1

31st March 2026, 6:58 pm

Published by Other Websites

External media mentions & references

Novartis Cancer Drug Patent Row: Delhi HC Slams Patent Office Over Decade Delay

18th March 2026, 1:22 am

Global Tariffs Loom as Indian Stocks Brace for Fraud, FDA Scrutiny

23rd February 2026, 8:10 am

Novartis India Exit: ChrysCapital-led Group Buys Stake for ₹1,446 Cr

21st February 2026, 10:30 am

Novartis Dumps India Unit for $180M; PE Firm ChrysCapital Buys Legacy Business

21st February 2026, 8:13 am

Novartis India Open Offer Launched: Rs 860 Share Price for 26% Stake

21st February 2026, 12:32 am

News Articles

Editorial & research coverage

India Budget 2026: Drug Duty Cuts Offer Targeted Relief
India Budget 2026: Drug Duty Cuts Offer Targeted Relief

3rd February 2026, 11:08 am

Novartis Bets Big on India: Country Poised to Become Global R&D Powerhouse!
Novartis Bets Big on India: Country Poised to Become Global R&D Powerhouse!

17th December 2025, 6:22 pm

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

2d - Certificate As per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations , 2018 for the quarter ended December 31, 2025, issued to Novartis India …

Board Meeting Intimation for Intimation Of The Meeting Of Board Of Novartis India Limited To Inter Alia, Consider And Approve The Unaudited Financial Results For Quarter Ended December 31, 2025.

30 Dec - Board meeting Jan 28, 2026 to approve unaudited Q3 results; trading window closed Jan 1, 2026.

Closure of Trading Window
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 (The 'Listing Regulations')

24 Nov 2025 - Commissioner Appeals upheld Service Tax demand INR 15,01,762; penalties INR 15,03,762; total INR 30,05,524; appeal planned.

Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

24 Nov 2025 - Appeals Commissioner confirmed Service Tax demand INR15,01,762; penalty INR15,03,762; total INR30,05,524; company to appeal.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Credit Ratings

No credit ratings.

Concalls

No concalls.

Stock Analysis

Description

Novartis India Ltd is primarily engaged in the pharmaceutical business, focusing on importing medicines and operating in areas such as pain management, organ transplantation, and neuroscience.

Key Growth Triggers

Currently no data available for Key Growth Triggers.

Order Book

Currently no data available for Order Book.

Key Red Flags

  1. A CENVAT Credit demand of INR 15.01 lakhs for FY 2014-15, with total demand (interest and penalties) of INR 30.05 lakhs, is currently under appeal.

Key Dates To Watch

  1. January 28, 2026: Board meeting to approve the Q3 FY26 financial results.

Corporate Announcements

17th Apr 26
Impact Rating: -
No description available.
13th Apr 26
Impact Rating: 6
Novartis India Limited complies with SEBI regulations by submitting a dematerialisation confirmation certificate for the financial year ended March 31, 2026.
13th Apr 26
Impact Rating: -
No description available.
7th Apr 26
Impact Rating: 9
Novartis AG has disclosed its agreement to sell 1,74,50,680 equity shares, constituting 70.68% of Novartis India's capital, to WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners.
31st Mar 26
Impact Rating: 9
Novartis India's Board will convene on May 12, 2026, to approve audited financial results for the year ended March 31, 2026. As per SEBI norms, the trading window for designated persons and their relatives closes from April 1, 2026.